The mutation p.V777L in exon 20 of the ERBB2 gene is already described as an activating mutation that likely drives tumorigenesis in breast cancer and it can be found in 1.6–2.0% of breast cancer patients and in about 6.0% of ERBB2-mutated patients [31]. This evidence concerns the gene ERBB2 and breast carcinoma.